Dr. Reddys Laboratories has launched Ezetimibe and Simvastatin Tablets, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mg a therapeutic equivalent generic version of Vytorin (Ezetimibe and Simvastatin) Tablets in the United States market, approved by the U.S. Food and Drug Administration (USFDA). Dr. Reddy’s is among the first companies to launch the generic product in the U.S. market.
The Vytorin brand had U.S. sales of approximately $678 million MAT for the most recent twelve months ended in February 2017 according to IMS Health. Dr. Reddy’s Ezetimibe and Simvastatin Tablets are available in bottle count sizes of 30, 90 and 1000. Vytorin is a registered trademark of MSD International GmbH.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.